Quantcast
Last updated on April 24, 2014 at 21:24 EDT
Researchers Discover Biomarker Leading To Cancer Drug

Researchers Discover Biomarker Leading To Cancer Drug Resistance

redOrbit staff & Wire Reports – Your Universe Online Researchers from the University of California, San Diego School of Medicine have located a biomarker that they believe could help explain why many of the medications used to treat...

Latest chemotherapy Stories

2014-04-24 10:55:15

The American Society for Radiation Oncology (ASTRO) has issued a new guideline, “The Role of Postoperative Radiation Therapy for Endometrial Cancer: An ASTRO Evidence-Based Guideline,” that details the use of adjuvant radiation therapy in the treatment of endometrial cancer. The guideline’s executive summary is published in the May-June 2014 issue of Practical Radiation Oncology (PRO), the official clinical practice journal of ASTRO. The full-length guideline is available as an...

2014-04-23 16:29:46

MARINA DEL REY, Calif., April 23, 2014 /PRNewswire/ -- Join Prostate Oncology Specialists for an educational talk about PROVENGE - a treatment to stimulate the immune system for advanced prostate cancer. Prostate cancer specialist, Dr. Jeffrey Turner, presents and reviews key topics: Why PROVENGE might be right for me? How do I know the PROVENGE treatment is working?How is PROVENGE different from hormone or chemotherapy?Does PROVENGE affect my PSA?How does PROVENGE boost my immune...

2014-04-23 08:31:00

Third Phase 3 Trial of Custirsen to Receive FDA Fast Track Designation BOTHELL, Wash. and VANCOUVER, British Columbia, April 23, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of custirsen when administered in combination with cabazitaxel/prednisone for the treatment of men with metastatic castrate-resistant prostate cancer (CRPC) following...

2014-04-22 08:33:21

Expanded Reimbursement in Canada and Inclusion in Leading German Physician Guidelines Increase Genomic Health's Impact in Key International Markets REDWOOD CITY, Calif., April 22, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced two important international milestones including additional reimbursement in Canada and the inclusion of the Oncotype DX(®) breast cancer test in major German clinical guidelines. In Canada, the BC Cancer Agency in British Columbia...

2014-04-19 23:00:54

Japanese research suggests a biomarker called osteopontin could help some mesothelioma patients avoid the trial-and-error approach to treatment. Raleigh, NC (PRWEB) April 19, 2014 Scientists say testing for the structural glycoprotein osteopontin in mesothelioma tissue samples could help streamline the process of selecting an effective treatment. Details on the new study have just been posted on the Cancer Monthly website and can be read by clicking here. Doctors in the Department of...

2014-04-18 12:30:44

Scientists have identified new pain relief targets that could be used to provide relief from chemotherapy-induced pain. BBSRC-funded researchers at King's College London made the discovery when researching how pain occurs in nerves in the periphery of the body. Dr Marzia Malcangio said: "We have been investigating and identifying mechanisms underlying pain generation and our findings could help chemotherapy patients who suffer pain related side effects." One potential side effect of...

2014-04-17 08:28:08

Company also announces designation of Orphan Drug Status by FDA for VTX-2337 in Ovarian Cancer SEATTLE, April 17, 2014 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc. today announced that enrollment has been completed in GOG-3003 (NCT01666444), a randomized, placebo-controlled Phase 2 trial of VTX-2337 in combination with Pegylated Liposomal Doxorubicin (PLD) in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer who have failed prior...

2014-04-15 08:29:16

Trial Will Evaluate Investigational Compound's Efficacy and Safety as an Addition to Standard Chemotherapy in Previously-Untreated Patients NORTH CHICAGO, Ill., April 15, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced the initiation of a global Phase III clinical trial evaluating the safety and efficacy of its investigational compound, veliparib (ABT-888), in patients with previously untreated locally advanced or metastatic squamous non-small cell lung cancer (NSCLC). The trial...

2014-04-13 23:00:43

Transparency Market Research Report Added "Anti-Tumor Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019" to its database. Browse Full Report: http://www.transparencymarketresearch.com/anti-tumor-drugs-market.html. Albany, New York, USA (PRWEB) April 13, 2014 Tumor is also termed as neoplasm and it is caused by an abnormal proliferation of tissues. This abnormal proliferation can be due to genetic mutations. Tumors can be...

2014-04-10 23:24:17

Mexican researchers say an alternative to the standard mesothelioma chemotherapy regimen can not only improve survival and quality of life, but can also save money. Raleigh, NC (PRWEB) April 10, 2014 Scientists in the Thoracic Oncology Unit at Mexico’s National Cancer Institute say continuous infusions of low-dose Gemzar (gemcitabine) with cisplatin appear to be a safe and effective alternative to standard mesothelioma chemotherapy. Click here to read about the new study on the...


Latest chemotherapy Reference Libraries

Intravenous Therapy
2013-04-30 13:16:16

Intravenous therapy, commonly known as IV therapy, is known as the administration of a liquid substance directly into a vein. It is also known as drip therapy, because most often the liquid is suspended above the IV site by an infusion pump, and runs through a drip chamber, which prevents air from entering the line. IVs are the preferred method of drug administration in hospital settings because they are the fastest known route of getting medication to the body. Intravenous therapy can also...

Antiviral Chemistry & Chemotherapy
2012-04-25 09:59:26

Antiviral Chemistry & Chemotherapy is a peer-reviewed academic journal published bi-monthly by International Medical Press in London since 1997. When founded in January 1990, it was published by Blackwell Science. The current editor-in-chief is Hugh J. Field of University of Cambridge, UK. The journal publishes primary papers and reviews on all aspects of the preclinical development of antiviral agents, including their chemical synthesis, biochemistry, pharmacology, mode of action and...

More Articles (2 articles) »